Vetoquinol SA (LON:0O1O)

Market Cap	766.88M
Revenue (ttm)	456.36M
Net Income (ttm)	51.39M
Shares Out	n/a
EPS (ttm)	4.37
PE Ratio	14.92
Forward PE	14.40
Dividend	0.75 (1.01%)
Ex-Dividend Date	Jun 4, 2025

Volume	23
Average Volume	89
Open	74.10
Previous Close	75.20
Day's Range	73.60 - 74.10
52-Week Range	64.50 - 85.60
Beta	0.75
RSI	44.03
Earnings Date	Oct 31, 2025

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1933
• Employees: 2,501
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0O1O

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.69 million, an increase of 5.62%.

Financial numbers in EUR